Evidence map›Paper›PMID 29336721›Full record

ArticlemAbs2018

Using hydrogen peroxide to prevent antibody disulfide bond reduction during manufacturing process.

Cheng Du, Yunping Huang, Ameya Borwankar, Zhijun Tan, Anthony Cura, Joon Chong Yee, Nripen Singh, Richard Ludwig, Michael Borys, Sanchayita Ghose and 2 more

Open access · goldAbstract read
In one paragraph

Article in mAbs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Cheng Dua Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.ORCID 0000-0002-8882-2513
Yunping Huangb Molecular and Analytical Development, Bristol-Myers Squibb Company , Pennington , NJ , USA.
Ameya Borwankara Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.
Zhijun Tana Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.
Anthony Curaa Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.
Joon Chong Yeea Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.
Nripen Singha Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.
Richard Ludwigb Molecular and Analytical Development, Bristol-Myers Squibb Company , Pennington , NJ , USA.
Michael Borysa Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.
Sanchayita Ghosea Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.
Nesredin Mussaa Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.
Zheng Jian Lia Biologics Process Development, Bristol-Myers Squibb Company , Devens , MA , USA.
Bristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During large-scale monoclonal antibody manufacturing, disulfide bond reduction of antibodies, which results in generation of low molecule weight species, is occasionally observed. When this happens, the drug substance does not meet specifications. Many investigations have been conducted across the biopharmaceutical industry to identify the root causes, and multiple strategies have been proposed to mitigate the problem. The reduction is correlated with the release of cellular reducing components and depletion of dissolved oxygen before, during, and after harvest. Consequently, these factors can lead to disulfide reduction over long-duration storage at room temperature prior to Protein A chromatography. Several strategies have been developed to minimize antibody reduction, including chemical inhibition of reducing components, maintaining aeration before and after harvest, and chilling clarified harvest during holding. Here, we explore the use of hydrogen peroxide in clarified harvest bulk or cell culture fluid as a strategy to prevent disulfide reduction. A lab-scale study was performed to demonstrate the effectiveness of hydrogen peroxide in preventing antibody reduction using multiple IgG molecules. Studies were done to define the optimal concentration of hydrogen peroxide needed to avoid unnecessary oxidization of the antibody products. We show that adding a controlled amount of hydrogen peroxide does not change product quality attributes of the protein. Since hydrogen peroxide is soluble in aqueous solutions and decomposes into water and oxygen, there is no additional burden involved in removing it during the downstream purification steps. Due to its ease of use and minimal product impact, we demonstrate that hydrogen peroxide treatment is a powerful, simple tool to quench reducing potential by simply mixing it with harvested cell culture fluid.

Indexed as

Antibodies, MonoclonalImmunoglobulin GAnimalsCHO CellsChromatography, AffinityCricetulusDisulfidesHydrogen PeroxideOxidation-ReductionRecombinant ProteinsStaphylococcal Protein AAntibodies, MonoclonalDisulfidesHydrogen PeroxideImmunoglobulin GRecombinant ProteinsStaphylococcal Protein Aantibodydisulfide bondshydrogen peroxidemAb manufacturingreduction

Identifiers

PMID29336721
PMCPMC5916552
OpenAlexW2783768542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.